[Medical oncology treatment]

Céline Chedeville; Hortense Reynes; Katia Nobre; Marc-Antoine Benderra

doi:10.1016/j.sger.2022.09.004

[Medical oncology treatment]

Soins Gerontol. 2022 Sep-Oct;27(157):13-17. doi: 10.1016/j.sger.2022.09.004. Epub 2022 Sep 13.

[Article in French]

Authors

Céline Chedeville¹, Hortense Reynes¹, Katia Nobre², Marc-Antoine Benderra³

Affiliations

¹ Département d'oncologie médicale, Hôpital Tenon, AP-HP, 4 rue de la Chine, 75020 Paris, France.
² Département d'oncologie médicale, clinique Hartmann, 26 bd Victor-Hugo, 92200 Neuilly-sur-Seine, France.
³ Département d'oncologie médicale, Hôpital Tenon, AP-HP, 4 rue de la Chine, 75020 Paris, France; Département d'oncologie médicale, clinique Hartmann, 26 bd Victor-Hugo, 92200 Neuilly-sur-Seine, France; IUC, AP-HP Sorbonne Université, 75000 Paris, France. Electronic address: [email protected].

PMID: 36280366
DOI: 10.1016/j.sger.2022.09.004

Abstract

Although patients over 65 years of age represent the majority of breast cancer patients, we have limited data on the safety and efficacy of medical oncology treatments in this population. Their indications are based primarily on expert agreement. This literature review discusses the known data on the safety and efficacy of the main medical treatments for breast cancer: chemotherapy, cytokine-dependent kinase inhibitors 4/6, agents targeting human epidermal growth factor receptor-2, novel antibody conjugates, and immunotherapy.

Keywords: breast cancer; cancer du sein; elderly; medical oncology treatment; sujet âgé; traitement oncologique médical.

Publication types

Review
English Abstract

MeSH terms

Breast Neoplasms* / drug therapy
Breast Neoplasms* / metabolism
Cytokines / therapeutic use
Female
Humans
Medical Oncology

Substances

Cytokines